Meeting
2013 ASCO Annual Meeting
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).
Authors
David Shao Peng Tan
Princess Margaret Cancer Center, Toronto, ON, Canada
David Shao Peng Tan , Christian K. Kollmannsberger , Sebastien J. Hotte , David W. Cescon , Ivan Diaz-Padilla , David W. Hedley , Daniel John Renouf , Albiruni R.A. Razak , Karen A. Gelmon , Hal W. Hirte , Lisa Wang , Monika Wizemann , Jeffrey Moscow , Helen X. Chen , Lillian L. Siu , Philippe L. Bedard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Angiogenesis
Clinical Trial Registration Number
NCT01548482
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2534)
DOI
10.1200/jco.2013.31.15_suppl.2534
Abstract #
2534
Poster Bd #
1B
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I study of ARQ 197 in combination with temsirolimus in advanced solid tumors.
First Author: Christos Kyriakopoulos
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk